HIGH-RISK PCI | MCS SUPPORT

Sunday, February 26, 2023

8:00 AM – 10:00 AM ET

Moderator(s)

David E. Kandzari, MD, FACC, FSCAI

Director, Interventional Cardiology, Piedmont Heart Institute; Chief Scientific Officer, Piedmont Healthcare
Piedmont Heart Institute
Atlanta, Georgia, United States

Disclosure(s): Medtronic: Advisor (Ongoing), Clinical Trial Investigator (Ongoing), Clinical Trial Support (Ongoing), Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing)
Jeffrey W. Moses, MD, FSCAI

John and Myrna Daniels Professor of Cardiology
Columbia University Medical Center
New York, New York, United States

Disclosure(s): Covanos: Stock-privately held company (Ongoing); Orchestra Biomed: Stock-privately held company (Ongoing); Ostial: Stock-privately held company (Ongoing); Weightless Lead: Stock-privately held company (Ongoing); Xenter: Stock-privately held company (Ongoing)
Samin K. Sharma, MD

Senior Vice-President, Operations & Quality
Mount Sinai Hospital
New York, New York, United States

No relationships to disclose

Disclosure(s):

David E. Kandzari, MD, FACC, FSCAI: Medtronic: Advisor (Ongoing), Clinical Trial Investigator (Ongoing), Clinical Trial Support (Ongoing), Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Contracted Research (Ongoing)

Jeffrey W. Moses, MD, FSCAI: Covanos: Stock-privately held company (Ongoing); Orchestra Biomed: Stock-privately held company (Ongoing); Ostial: Stock-privately held company (Ongoing); Weightless Lead: Stock-privately held company (Ongoing); Xenter: Stock-privately held company (Ongoing)